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Introduction
More than 98 per cent of the 10.630 million children
under 5 years of age who die each year are in
developing countries and acute respiratory infections
(ARI) are accountable for 4 million of those deaths.
Pneumonia is thought to arise from inhalation of
Streptococcus pneumoniae (SP) or Haemophilus
influenzae (HI) present in nasopharyngeal secre-
tions. One of the World Health Organization’s
(WHO) main objectives in the Integrated Manage-
ment of Childhood Illness (IMCI) is the prevention
of death due to pneumonia. It also emphasizes that
case management of pneumonia is the major area
where improvement is still needed. It recommends
that any child under 5 years of age presenting at a
first-level health center with a cough or respiratory
distress should have a thorough examination to
exclude possible pneumonia. Assessment should
verify rate of respiration, chest indrawing, cyanosis
and feeding ability,1 and thus enable sequential and
rational administration of antimicrobials. Incidence
of SP and HI in nasopharyngeal aspirates has been
established in many different countries and settings;1
it has also been established that SP and HI are the
predominant pathogens involved in childhood pneu-
monia in developing countries.2,3 WHO has recom-
mended data collection on antimicrobial resistance
for each country, but few trials have provided data
concerning ARI in rural communities,4,5 and none in
Senegal. Lung biopsy or needle aspirations are the
only methods that assertively demonstrate the
etiology of bacterial pneumonia. However, it has
been shown that micro-organisms detected in lung
aspirates are present 80 per cent of the time in
children’s nasopharynx. The converse is often true
and, based on WHO methodology, nasopharyngeal
sampling has been shown to give valid results.6,7
Another assumption is that organisms found in the
nose of children who do not have pneumonia are
similar to those found in the lungs of children who do
have pneumonia.6,8,9 Nasopharyngeal aspirates are
thus a suitable substitute for lung aspirate for the
determination of the type of pathogens involved in
ARI and their susceptibility to antibiotics. In this
regard antibiotic susceptibility tests occupy a central
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Summary
Acute respiratory infections (ARI) are still a major health problem in most developing countries.
So far no study has evaluated the importance of childhood ARI in rural Senegal. We prospectively
studied ARI, the percentage of pneumonia and related mortality, as well as the bacterial composi-
tion of nasopharyngeal flora using nasopharyngeal aspirates in 114 children, aged 2–59 months,
presenting at Ndioum’s pediatric ward. Excluded from the trial were those children that had had
antimicrobial therapy in the previous 2 weeks.The Kirby–Bauer method was used to determine anti-
biotic resistance throughout the study. The percentage of ARI and pneumonia among the popu-
lation tested was 24 per cent and 11 per cent respectively. Streptococcus pneumonia was often
resistant to cotrimoxazole (31 per cent) but only 9 per cent were resistant to chloramphenicol and
14 per cent to penicillin. Haemophilus influenzae (HI) was uniformly sensitive to ampicillin, and
only 4 per cent were resistant to chloramphenicol and 11 per cent to cotrimoxazole. We conclude
that SP and HI resistance to cotrimoxazole is important and warrants larger clinical trials using chlo-
ramphenicol. Information campaigns and intense management of comorbidities are desirable in this
type of population. Comorbidities (tuberculosis, malaria, HIV-AIDS, severe malnutrition) are
determinant variables in many ARI cases and carry a high negative prognosis value.
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position because it has been established that clinical
efficacy is directly related to antibiotic susceptibil-
ity.10 The goals of this study, which was conducted at
Ndioum’s rural hospital in Senegal and involved
children aged 2–59 months old, were to evaluate the
percentage of ARI and pneumonia in the population
tested, to establish the bacterial composition of
nasopharyngeal flora and its in vitro resistance, and
to correlate in vitro susceptibility or resistance with
clinical evolution in children with WHO-defined
pneumonia.
Patients and Methods
From March to May 2000, we prospectively enrolled
all children aged between 2 and 59 months present-
ing at Ndioum’s hospital pediatric service. Excluded
from the trial were those children that had had
antimicrobial therapy in the previous 2 weeks.
Verbal parental consent as well as approval from the
hospital director was obtained. The hospital is the
main care provider of the Saint-Louis district, apart
from the Saint-Louis hospital which is 5 h away, and
the pediatric service covers a population of 100 000
children under 16 years of age. Five thousand
consultations and 1000 hospitalizations take place
every year at the ward. Parents sometimes report
that they have been travelling for 10 days when they
arrive at the ward. Infectious diseases are the
primary cause of hospitalization. The national vacci-
nation programme is well accepted by the population
and coverage is good, but it does not include
Haemophilus influenzae type b vaccine. For each
children, details of the clinical examination made
upon arrival were recorded on a standardized form.
Specimen collection and processing
Nasopharyngeal aspirate was taken at admission
from every child, using a suction set or a child’s
feeding tube connected to suction. Sampling and
child identification were done at the first visit to the
clinic and no subsequent sampling was done even if
the child presented at a later time during the study. A
tube was passed along the inferior nasal wall until it
reached the posterior nasopharyngeal wall. Suction
was then activated and left on for about 3 s. It was
stopped before withdrawal of the tube. Specimens
were immediately brought to the laboratory and
processed. All laboratory procedures and methods
were carried out in accordance with WHO guide-
lines.11 A standardized laboratory form was used for
each child. For each nasopharyngeal sample, a Gram
stain was done. In accordance with WHO
recommendation, samples that had more than 25
epithelial cells at 100 were rejected.12 All others
were immediately inoculated onto three solid media:
a trypticase soy agar plate containing 5 per cent
sheep blood with an optochin disk on the site of inoc-
ulation; a chocolate blood agar plate containing 
bacitracin (10 UI/ml); and a MacConkey agar plate.
The sheep blood and chocolate agar plates were
incubated at 37 ºC in a candle extinction jar while the
MacConkey agar plate was incubated at 37 ºC
without special atmosphere. Bacterial growth was
recorded after 24 h of incubation and semi-quantita-
tive evaluation was done using the four-quadrant
method.
Bacterial identification and susceptibility testing
The Kirby–Bauer method, accepted by the WHO as
a standard testing method,12 was used to determine
antibiotic resistance throughout the study. SP was
identified by typical colony morphology, alpha-
hemolysis on sheep blood agar, susceptibility to
optochin (zone of inhibition > 14 mm) and bile solu-
bility. HI was identified by typical colony morphol-
ogy on chocolate blood agar with bacitracin and by
growth requirements for nicotinamid adenine dinu-
cleotide (factor V) and haemin (factor X). Using the
disc diffusion method, SP and HI were tested against
penicillin, cotrimoxazole, chloramphenicol and
ampicillin, cotrimoxazole, and chloramphenicol,
respectively. In vitro susceptibility of SP isolates to
oxacillin (for penicillin) (1 µg), cotrimoxazole
(1.25/23.75 µg) and chloramphenicol (30 µg) was
tested on a Mueller–Hinton agar plate containing 5
per cent sheep blood and incubated at 37 ºC in a
candle extinction jar, in accordance with National
Committee for Clinical Laboratory Standards
recommendations.13 SP isolates with an inhibition
zone diameter ≤ 19 mm for oxacillin (no equivalent
MIC breakpoint), ≤ 15 mm for cotrimoxazole
(equivalent MIC breakpoint ≥ 4/76 µg/l) and ≤ 20
mm for chloramphenicol (equivalent MIC break-
point ≥ 8 µg/l) were defined as resistant. Technical
limitations prevented us from performing MIC
testing on SP isolates that had a zone of inhibition 
> 13 mm but < 20 mm for oxacillin, as recommended
by the NCCLS. This limits the interpretation of the
results for the strains falling in this category to
‘probably moderately resistant’ to penicillin instead
of a clear-cut result of resistant or insensitive. SP
isolates with an inhibition zone diameter ≥ 20 mm for
oxacillin (equivalent MIC breakpoint ≤ 0.6 µg/l), 
≥ 19 mm for cotrimoxazole (equivalent MIC break-
point ≤ 0.5/9.5 µg/l) and ≥ 21 mm for chlorampheni-
col (equivalent MIC breakpoint ≤ 4 µg/l) were
defined as being susceptible. Zones for inhibition
found to be between resistant and susceptible
categories were declared intermediate to those
antibiotics, except for oxacillin and chloramphenicol,
which do not have an intermediate zone of inhibi-
tion.
In vitro susceptibility testing of HI isolates to
ampicillin (10 µg), cotrimoxazole (1.25/23.75 µg) and
chloramphenicol (30 µg) was performed on a HTM
plate and incubated at 37 ºC in a candle extinction
jar.13 HI isolates with an inhibition zone diameter
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≤ 18 mm for ampicillin (equivalent MIC breakpoint
≥ 4 µg/l), ≤ 10 mm for cotrimoxazole (equivalent MIC
breakpoint ≥ 4/76 µg/l) and ≤ 25 mm for chlo-
ramphenicol (equivalent MIC breakpoint ≥ 8 µg/l)
were defined as resistant. HI isolates with an inhibi-
tion zone diameter ≥ 22 mm for ampicillin (equival-
ent MIC breakpoint ≤ 1 µg/l), ≥ 16 mm for
cotrimoxazole (equivalent MIC breakpoint ≤ 0.5/9.5
µg/l) and ≥ 29 mm for chloramphenicol (equivalent
MIC breakpoint ≤ 2 µg/l) were defined as susceptible.
Zones of inhibition found to be between resistant
and susceptible categories were declared inter-
mediate to those antibiotics, except for chloram-
phenicol, which does not have an intermediate zone
of inhibition.
Results
One hundred and forty children aged 2–59 months
were examined; 12 had received antibiotics in the
previous 2 weeks and were excluded. Nasopharyn-
geal aspirates were taken from 128 children and 14 of
them did not meet minimal quality criteria. Thus 114
children (52 girls, 62 boys; mean age 17.8 months, 64
per cent under 2 years) were included in the study.
The principal indication for consultation were
diarrhea (n = 37, 32 per cent), ARI (n = 27, 24 per
cent), fever (n = 7, 6 per cent), and measles (n = 6, 5
per cent). Twenty-six children (23 per cent) were
malnourished with a weight/height ratio < 60 (n = 17,
15 per cent) or between 60 and 80 (n = 9, 8 per cent).
Twenty-nine children were hospitalized and eight
died during the hospital stay, three within 24 h and
five later.
Table 1 shows the isolation percentages of patho-
genic bacteria and their susceptibility profiles.
Isolation percentages from nasopharyngeal aspirates
were 56 per cent for SP (64/114) and 46 per cent for
HI (53/114). Seventy-three per cent (83/114) of
children had a flora containing SP, HI or both.
Nasopharyngeal aspirate revealed SP alone in 30
cases (26 per cent), HI alone in 19 cases (17 per cent),
both in 34 cases (30 per cent), and neither of them in
31 cases (27 per cent). Among 114 children, 27
presented signs of ARI according to WHO. Table 1
also compares nasopharyngeal carriage percentages
and resistance in patients with and without ARI
based on WHO definition. SP and HI carriage
percentages are not statistically different between
these two groups ( ≤ 0.05).
Overall resistance to cotrimoxazole was shown in
31 and 11 per cent of SP and HI isolates, respectively.
In contrast, ampicillin was uniformly active against
HI isolates. Multidrug resistance concerned 11
isolates (nine SP: three Peni-Cotri, six Chlor-Cotri,
and two HI both Chlor-Cotri). All pathogens but one
from children presenting with ARI were susceptible
to chloramphenicol. Age (less than or greater than 2
years as in the literature) was not found to be a 
determining factor for carriage and resistance
percentages.
Twelve cases of pneumonia (seven of class 2, five
of class 3) were diagnosed, representing 11 per cent;
all were seen in children < 2 years (six girls, six boys;
mean age 14 months), with a mortality rate of 33 per
cent (4/12). Fifty per cent (4/8) of all children dying
during this study had pneumonia. All 12 children
with pneumonia were hospitalized and antimicrobial
therapy was instituted. Of major concern was the
delay in arrival at the hospital, which put children at
risk and is reflected in the rapid fatal evolution
(within 48 h) for four of the eight children who died
during this study. Antimicrobial susceptibility corre-
lated well with clinical outcome in three children.
One child’s outcome was favorable in spite of in vitro
resistance to the antibiotic prescribed. He was free of
any major comorbidity. Two children died, even
though their flora was susceptible to the anti-
microbial given, probably due to severe comorbidi-
ties (tuberculosis and malaria) as well as malnutri-
tion. Five of the 12 children with pneumonia had a
flora containing neither SP nor HI; two of these five
children died within 48 h of admission.
Discussion
An estimated 5000 consultations take place at
Ndioum’s pediatric service each year. Its remote
location, extreme climate, and lack of communi-
cation render healthcare delivery very difficult while
favoring delay in child hospitalization. We surveyed
114 children aged 2–59 months (64 per cent under 2
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TABLE 1
Carriage and resistance percentagesa in children,
based on the presence or absence of WHO-defined
ARI
Children Overall resistance n (%)
S. pneumoniae H. influenzae
With ARI (n = 27)
Pen or Ampb 3/17 (18) 0/10 (0)
Cotrimoxazole 7/17 (41) 2/10 (20)
Chloramphenicol 0/17 (0) 1/10 (10)
Without ARI (n = 87)
Pen or Amp 6/47 (13) 0/43 (0)
Cotrimoxazole 13/47 (28) 4/43 (9)
Chloramphenicol 6/47 (13) 1/43 (2)
All children (n = 114)
Pen or Amp 9/64 (14) 0/53 (0)
Cotrimoxazole 20/64 (31) 6/53 (11)
Chloramphenicol 6/64 (9) 2/53 (4)
a For the definition of penicillin resistance in SP, see Patients
and Methods section.
b Penicillin for SP, Ampicillin for HI.
years of age) from March to May 2000. Pneumonia as
defined by WHO concerned children < 2 years
exclusively. Tambe, et al.,5 reported the highest pneu-
monia prevalence in the less-than-2-year age group.
The percentage of ARI was 24 per cent (27/114)
while that of pneumonia was 11 per cent and mortal-
ity among this latter group was 33 per cent (4/12),
representing 50 per cent (4/8) of all deaths occurring
during this study. The percentage of ARI was
recorded as being between 7.6 and 26.8 per cent in
Tanzania, India and Egypt5,14–16 and a higher
percentage in children between 6 and 24 months was
noted in India.5 Our collective results are a good
indicator of the pediatric population encountered in
rural north-east Senegal in particular and provide a
valid estimate of a rural Third World population in
general.
This study, realized in the field, has the following
limitations. First, cultures were obtained from
nasopharyngeal aspirates and not lung aspirates or
blood. Second, aspirates were taken from all children
even though most of them did not have ARI. Third,
we did not test urine for antibiotic activity. This
suggests that we underestimated carriage percent-
ages and overestimated resistance percentages.17
Lastly, isolates were not serotypes. The limits of
nasopharyngeal aspirations as a means of detecting
SP or HI were revealed by the 50 per cent SP and/or
HI yield; 27 per cent of the specimens were free of
either SP or HI and 42 per cent of specimens from
children with pneumonia revealed neither SP nor HI.
It must be noted, however, that for the limited
number of cases of pneumonia we encountered, no
systematic correlation between in vitro susceptibility
patterns and clinical evolution could be established.
No particular correlation could be established either
between age and type and intensity of colonization.
Carriage percentages revealed a clear cleavage
between developing and developed countries, the
former disclosing consistently higher carriage
percentages than the latter. Regarding nasopharyn-
geal carriage of SP or HI, our data are similar to
reports from other Third World countries, particu-
larly from Central Africa Republic (CAR)18 and
Egypt.8 Higher SP carriage percentages were
reported from Gambia (98 per cent), Papua New-
Guinea (98 per cent), Kenya (89 per cent), Dakar-
Senegal (72 per cent), Zambia (72 per cent), Pakistan
(61 per cent), and South Africa (56 per cent) and a
lower rate from Virginia, USA (39 per cent).1,6,19,20
HI carriage was reported from Pakistan (43 per cent)
and South Africa (42 per cent) and HI type b from
Gambia (13 per cent), Kenya (9 per cent), Papua
New-Guinea (6 per cent), and Wales, UK (1 per
cent).1,10,19,20 Because few studies have tested anti-
biotic activity, differences in carriage percentages of
HI and SP may have been due to variations in the
proportion of children who recently had antibiotics.
Regarding antibiotic resistance, a significant SP in
vitro resistance percentage to cotrimoxazole (31 per
cent) was found, as well as complete susceptibility of
HI isolates to ampicillin. Resistance of SP and HI
was in the high range when compared with data from
other developing countries. Resistance was highest
against cotrimoxazole (31 per cent), an antimicrobial
agent broadly used in that part of Senegal as a first-
line agent, particularly in feverish children and in
areas where malaria is endemic. This has been shown
to increase percentages of resistant SP.21 Most SP
and HI isolates were susceptible to chloramphenicol
and ampicillin, respectively. SP resistance to peni-
cillin (7–14 per cent), cotrimoxazole (7–33 per cent)
and chloramphenicol (1–37 per cent) has been
reported from South Africa, Pakistan, CAR, and
Zambia.8,21 SP resistance to penicillin (43 per cent),
cotrimoxazole (46 per cent) and chloramphenicol (9
per cent) was reported from the USA.22 HI resist-
ance to cotrimoxazole (0–26 per cent), the higher
figure occurring in tuberculosis-infected children in
South Africa, and to chloramphenicol (0–36 per
cent) has been reported from the Philippines, Papua
New-Guinea, Thailand, and Pakistan.20,23,24 We
found no HI strains resistant to ampicillin (universal
or near universal susceptibility of HI isolates to
ampicillin has been reported in most developing
countries). These countries reported a low percent-
age of -lactamase positive HI strains when
compared with developed countries. It has been
reported that HI infections in children with tubercu-
losis showed a high degree of in vitro resistance to
conventional ARI treatment.20 Our unique case of
tuberculosis showed SP and HI isolates fully suscep-
tible. Rowe, et al.18 reported no significant difference
with regard to antimicrobial resistance between sick
children with and without WHO-defined pneu-
monia.
We observed similar carriage and resistance
percentages among children with and without ARI
as defined by WHO (Table 1). Age was not a predic-
tive factor for SP or HI colonization among our
population. As in CAR,18 perhaps another risk factor
for colonization is previous exposure to antibiotics;
however, our study did not include such patients.
Comorbidities associated with pneumonia (tuber-
culosis, malaria, HIV-AIDs, severe malnutrition)
carry a high negative prognostic value in terms of
outcome. Twelve WHO-defined pneumonia cases
were diagnosed during the study, a number that did
not allow us to test fully the correlation between in
vitro results and in vivo outcome. However, it is
obvious that ARI is one of the most prevalent
illnesses in north-east Senegal and its related mortal-
ity is elevated.
Conclusions
WHO guidelines have now been used for a long time
and have proved their efficacy in most situations.
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However ARI, and particularly pneumonia, still
carry a high mortality rate in most developing coun-
tries, as was the case in this study. Cotrimoxazole is
recommended as a first-line agent against pneumo-
nia in rural Senegal because of its few side-effects,
ease of administration, and low cost. However, in
vitro resistance to cotrimoxazole, particularly in SP
and (to a lesser degree) in HI, the two most prevalent
pathogens recovered in half of the patients, is of
concern. To establish the correlation between in vitro
susceptibility to antibiotics and clinical outcome,
using the few antimicrobials available in the Third
World, would necessitate large clinical studies. Infor-
mation on general health issues aimed at targeting
populations, as well as intense management of ARI
comorbidities, notably malnutrition, are desirable if
ARI’s death toll is to be reduced. Further studies
using chloramphenicol, found to be highly active in
this study and presently recommended only for
severe ARI, must be carried out in spite of its rare,
but feared, side-effects.
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